auranofin derivative STAT3 inhibitors (MD Anderson Cancer Center)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Nameauranofin derivative STAT3 inhibitors (MD Anderson Cancer Center)
Drug Alias NameWP-1531WP-1533
ClassificationSmall molecules
Mechanisms of ActionSignal transducer and activator of transcription 3 inhibitors
TargetsSignal transducer and activator of transcription 3
Therapy Area/IndicationsBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsBrain Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A